Long-term Pre-dialysis Extension in Europe and Asia Pacific

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

Also called NCT02055482

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02055482
  • EudraCT 2013-001190-24
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Bulgaria, France, Germany, Hungary, Israel, Italy, Japan, Poland, Romania, South Korea, Spain, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02055482. Randomized; no masking; primary purpose treatment. Start 2014-06-24 (actual); primary completion 2016-11-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Pre-dialysis Extension in Europe and Asia Pacific
Acronym
DIALOGUE 3
Condition
Anemia
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Molidustat (BAY85-3934)
Intervention (Biological)
Darbepoetin
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02055482
Content hash
09c2ecf01f4be23966d474e10251cf5fbf2bd15c4719323f40f8ff6bf9465f57